Finanzen von Agenus Inc (AGEN)AGENAgenus Inc

Agenus Inc (AGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Non-cash royalty revenue, accounting for 86.4% of total sales, equivalent to $29.14M. Another important revenue stream is Pre-commercial product revenue. Understanding this composition is critical for investors evaluating how AGEN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Agenus Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.72%, while the net margin is -1.64%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AGEN converts its operational activities into shareholder value.

In the context of the broader market, AGEN competes directly with industry leaders such as SABS and DMAC. With a market capitalization of $359.71M, it holds a significant position in the sector. When comparing efficiency, AGEN's gross margin of 100.00% stands against SABS's N/A and DMAC's N/A. Such benchmarking helps identify whether Agenus Inc is trading at a premium or discount relative to its financial performance.

Agenus reported a total revenue of $34.5 million for Q2 2026, a significant increase from $25.7 million in Q2 2025, indicating strong growth. The gross margin remains high at 100%, reflecting efficient cost management despite ongoing net losses.